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Aims: Sodium glucose co-transporter-2 (SGLT2) inhibition reduces heart failure (HF) 
hospitalizations in patients with diabetes, irrespective of glycemic control. We examined 
the effect of SGLT2 inhibition with empagliflozin (EMPA) on cardiac function in non-
diabetic rats with left ventricular (LV) dysfunction after myocardial infarction (MI). 
Methods and results: Non-diabetic male Sprague-Dawley rats underwent permanent 
coronary artery ligation to induce MI, or sham surgery. Rats received chow containing EMPA 
that resulted in an average daily intake of 30 mg/kg/day or control chow, starting before 
surgery (EMPA-early) or 2 weeks after surgery (EMPA-late). Cardiac function was assessed 
using echocardiography and histological and molecular markers of cardiac remodelling and 
metabolism were assessed in the left ventricle. Renal function was assessed in metabolic 
cages. 
EMPA increased urine production by two-fold without affecting creatinine clearance and 
serum electrolytes. EMPA did not influence MI size, but LV ejection fraction (LVEF) was 
significantly higher in the EMPA-early and EMPA-late treated MI-groups compared to the 
MI group treated with vehicle (LVEF 54%, 52% and 43% respectively, all P < 0.05). EMPA 
also attenuated cardiomyocyte hypertrophy, diminished interstitial fibrosis and reduced 
myocardial oxidative stress. EMPA treatment reduced mitochondrial DNA damage and 
stimulated mitochondrial biogenesis, which was associated with the normalisation of the 
myocardial uptake and oxidation of glucose and fatty acids. EMPA increased circulating 
ketone levels as well as the myocardial expression of the ketone body transporter and two 
critical ketogenic enzymes, indicating that myocardial utilization of ketone bodies was 
increased. Together these metabolic changes were associated with an increase in cardiac 
ATP production.
Conclusion: Empagliflozin favourably affects cardiac function and remodelling in non-
diabetic rats with LV dysfunction after MI, associated with substantial improvements 
in cardiac metabolism and cardiac ATP production. Importantly, it did so without renal 
adverse effects. Our data suggest that EMPA might be of benefit in HF patients without 
diabetes.
Keywords: Diabetes • Heart failure • Metabolism • Mitochondria • Renal function • 
Remodelling 




Type 2 diabetes mellitus (T2DM) and heart failure (HF) commonly coexist.1 Patients with 
T2DM have two-fold increased risk of developing HF during their lifetime,2,3 and are also 
twice as likely to be hospitalized for HF.4–6 
Cardiovascular events and HF hospitalizations can be reduced by adequate glycaemic 
control in patients with T2DM,7 but once HF develops the therapeutic options become 
limited.8–10 Currently, only metformin is considered safe in HF patients because other oral 
anti-diabetic drugs have suspected or established safety concerns in this population.1 This 
is not the case for SGLT2 inhibitors (SGLT2i), a new class of anti-diabetic drugs that have 
been shown to markedly reduce CV events and HF hospitalizations in patients with T2DM. 
SGLT2i are not only safe and well tolerated in patients with HF but also reduce the incidence 
of HF hospitalizations, both in subgroups of patients with and without HF at baseline.11,12  
SGLT-2 is a sodium-dependent glucose transporter expressed in the proximal tubule of the 
kidney and is responsible for 90% of the renal reabsorption of filtered glucose. Accordingly, 
SGLT2i induce urinary glucose and sodium excretion and promote diuresis.13 SGLT2i have 
relatively few side effects and rarely cause symptomatic hypoglycaemia, even when given 
to non-diabetic patients.14 SGLT2i have relatively modest effects on glycaemic control, 
suggesting that alternative mechanism may be responsible for the reductions in HF events, 
which may also apply to non-diabetic patients. The effects of SGLT2i on diuresis and HF 
hospitalisations without significant side-effects had prompted the hypothesis that SGLT2i 
could also be of benefit in HF patients, with or without T2DM. 
While this hypothesis is currently under investigation in several clinical trials,15,16 the effect 
of SGLT2 inhibition on outcomes in non-diabetic HF patients remains unclear at this 
point.17,18 We sought to determine the effect of the SGLT2i empagliflozin (EMPA) on cardiac 
function and remodelling after MI. 
METHODS
A detail description of methods is available in the supplementary Materials.
Experimental protocol
The experimental protocol was approved by the Animal Ethical Committee of University 
of Groningen (IvD number: 16487-02-001). The investigation conforms to the Guide for 
the Care and Use of Laboratory Animals published by the US National Institutes of Health. 
We followed ARRIVE guidelines when reporting this study.19 Non-diabetic male Sprague-
Dawley rats (Envigo, The Netherlands) were randomized to treatment with chow containing 




(late). Treatment allocation in the late groups was stratified according to left ventricular 
ejection fraction (LVEF) 2 weeks post-surgery to ensure that the baseline cardiac function 
is similar in the EMPA and the vehicle groups. After 10 weeks of treatment, rats were 
anesthetized, blood was drawn and the hearts were rapidly excised for further analysis. 
Rats with an infarct size of  less than 15% were excluded from analysis as these small infarcts 
are haemodynamically fully compensated.20
MI surgery 
Rats were randomized to permanent ligation of the left anterior descending coronary artery 
or sham surgery under isoflurane (2.5%) inhalation anaesthesia, as previously described.21 
Investigational drug
Empagliflozin (BI 10773) was kindly supplied by Boehringer Ingelheim, Germany. EMPA 
(BI 10773) was mixed with standard rat chow (R/M-H V1534-70, Ssniff, Germany) in a final 
concentration of 200 mg/kg intended to reach an average dose of 30 mg/kg/day. 
Echocardiography 
Two weeks after surgery and 1 week before termination, the M-mode and two-dimensional 
echocardiography was performed using a Vivid 7 echo machine (GE Healthcare, Milwaukee, 
WI, USA) equipped with a 10-MHz phase array linear transducer for serially assessment of 
cardiac structure and function as previously described.21,22 
Invasive hemodynamic measurements 
Prior to sacrifice, invasive haemodynamics were analysed by aortic and left ventricular 
(LV) catheterization, as previously described.21 The data were acquired using a PowerLab 
data acquisition system (ADInstruments, Colorado Springs, CO, USA) and analyzed with a 
LabChart 8 software.
Infarct size, cardiomyocyte size and interstitial fibrosis measurement 
For immunohistochemical analysis, the mid-papillary slice of the left ventricle was fixed in 
4% formaldehyde and paraffin-embedded. Masson trichrome staining was performed to 
evaluate the infarct size and the extent of interstitial fibrosis. Furthermore, to determine 
cardiomyocyte size, sections were stained with FITC Labelled wheat germ agglutinin (WGA) 
as previously described.21,22 
Metabolic cage 
Two weeks before termination, rats were placed in metabolic cages to monitor 24-hour 
water and food intake and 24-hour urine collection, as previously described.23 
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Blood and urine measurements 
Blood samples were obtained via tail vein at regular intervals under isoflurane anaesthesia 
to monitor blood glucose and haematocrit levels.  At sacrifice, 8 ml of blood was drawn from 
the abdominal aorta (either anti-coagulated with EDTA or sodium heparin), and urine was 
collected directly from bladder. 
Mitochondrial DNA (mtDNA)-to-nuclear DNA (nDNA) ratio and mtDNA damage
Total DNA including mtDNA was extracted from the non-infarcted left ventricle using 
Nucleospin® Tissue XS (Macherey-Nagel GmBH&Co. KG, Düren, Germany). mtDNA-
to-nDNA ratio was determined by quantitative real-time polymerase chain reaction 
(qRT-PCR), as described previously.24 Expression of mitochondrial genes were corrected 
for nuclear gene expressions values, and the calculated values were expressed relative to 
the control group per experiment. To determine DNA damage (lesions/10kb), the D-loop 
mitochondrial genomic region was amplified by a semi-long-run qRT-PCR, as described 
before.24 Primer sequences are listed in the supplementary Table S1.
Quantitative real-time polymerase chain reaction
RNA was extracted from the non-infarcted left ventricle using TRIzol reagent (Invitrogen 
Corp., Carlsbad, CA, USA) and QuantiTect RT kit (Qiagen) was then used to make cDNA, 
following manufacturer’s instructions as previously described.25 36B4 reference gene 
were used to correct all measured mRNA expression. Primer sequences can be found in 
supplementary Table S1. 
Advanced oxidation protein products measurements
The advanced oxidation protein product (AOPP) assay was performed using the AOPP 
Assay Kit from Abcam (#ab242295, Cambridge, U.K.) according to the manufacturer’s 
instructions. Results were then normalized by protein concentrations of each test.
ATP measurements
The ATP assay was performed using the ATP Assay Kit (colorimetric/fluorometric) from 
Abcam (#ab83355, Cambridge, U.K.) according to the manufacturer’s instructions. Results 
were then normalized by protein concentrations of each test.
Pyruvate dehydrogenase activity 
According to manufacturer’s instruction, we measured the activity of pyruvate 
dehydrogenase (PDH) using the assay kit from Sigma MAK183 and a spectrophotometric 




Insulin and glucagon measurements
Circulating hormones were measured by a rat ultrasensitive insulin ELISA kit 
(80-INSRT-E01, ALPCO) and Glucagon ELISA (48-GLUHU-E01, ALPCO) according to the 
manufacturer’s instructions.
Statistical analysis 
Data are presented as means ± standard errors of the mean (SEM). To compare normally 
distributed parameters, one-way analysis of variance (ANOVA) followed by Tukey’s Post 
Hoc test was used. When data were not normally distributed, a non-parametric Kruskal-
Wallis test followed by a Mann-Whitney U test with correction for multiple comparisons 
was used. To compare EMPA and Vehicle treatment independent of treatment allocation, 
an independent T test or a Mann-Whitney U test was used, where appropriate. Wilcoxon 
signed rank test was used to evaluate LVEF post-MI versus before termination (Figure 
2E). Differences were considered significant at p<0.05. IBM SPSS Statistics for Windows, 
version 23.0 (IBM Corp., Armonk, NY, USA) was used to perform all statistical analysis. 
RESULTS
A total of 140 rats were randomized to MI or sham surgery, 47 rats died during the surgical 
procedure. Overall mortality in the MI groups was 41%. All rats died from ventricular 
fibrillation within 60 minutes of left anterior descending coronary artery ligation. No 
mortality was observed during the subsequent stages of the study and no mortality was 
observed in sham-operated rats throughout the study. There were no statistically significant 
differences in mortality between the MI-vehicle vs. the MI-EMPA-E or the MI-EMPA-L 
groups (43% vs. 40% vs. 40%, respectively). In total, 20 rats with infarct sizes of < 15% were 
excluded from analysis (8 rats in MI-vehicle group, 5 rats in MI-EMPA-E group and 7 rats in 
EMPA-L group), leaving a total of 73 rats for the current analysis. The final group sizes were 
8 for the sham-vehicle group, 19 for sham-EMPA group, 22 for MI-vehicle group, 13 for MI-
EMPA-early group and 11 for MI-EMPA-late group. 
Efficacy and safety of empagliflozin in non-diabetic rats with LV dysfunction after MI
Efficacy of empagliflozin
Daily food intake was comparable between EMPA and vehicle treated groups and the 
average daily dose of EMPA was 30 mg/kg of body weight/day (supplementary Figure S1A). 
As expected, EMPA increased urinary glucose (Figure 1A) and sodium excretion (Figure 1B), 
resulting in a 2-fold increase in urine production (Figure 1C). The increase in urinary glucose 
excretion was associated with a substantial reduction in body weight in the EMPA treated 
sham and MI groups (supplementary Figure S1C).




The increase in diuresis after EMPA treatment was compensated by a proportionate increase 
in fluid intake (Supplementary Figure S1B) and did not affect haematocrit (supplementary 
Figure S2A) or renal function (Figure 1D), indicating that EMPA did not cause excessive 
plasma contraction. In addition, EMPA did not cause significant changes in plasma glucose, 



































































































































FIGURE 1. Efficacy and safety of empagliflozin (EMPA) in non-diabetic rats with left ventricular dysfunction after 
myocardial infarction (MI). (A) 24 h urinary glucose excretion. (B) 24 h urinary sodium excretion. (C) 24 h urine 
production. (D) Creatinine clearance of all groups. EMPA-E, EMPA-early; EMPA-L, EMPA-late; Veh, vehicle. Data are 
presented as means ± standard errors of the mean. *p<0.05 vs. MI-Veh; #p<0.05 vs. Sham-Veh. 
Effect of empagliflozin on blood pressure and cardiac function
The average LV infarct size was 33% and did not differ among the MI, MI-EMPA-early 
and MI-EMPA-late groups (Figure 2A and 2B). Systolic and diastolic blood pressure was 
also not different between the groups (supplementary Table S2). As expected, MI resulted 
in significant LV dilatation (Figure 2C) and a reduction in LVEF (Figure 2D). LVEF was 
significantly higher in both MI-EMPA treated groups compared to the MI-vehicle group 
(Figure 2D) A pooled analysis of longitudinal changes in LVEF revealed that EMPA prevented 
the progressive deterioration of cardiac function that occurs after MI (Figure 2E). Other 
relevant echocardiographic parameters are depicted in supplementary Table S3. There was 
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Effect of empagliflozin on cardiac histology and molecular markers for remodelling 
and fibrosis
A large MI invariably causes pathological remodelling of the non-infarcted myocardium 
which contributes to further deterioration of cardiac performance.26–28 
Marked cardiac hypertrophy was observed after MI as reflected by a 10% increase in 
ventricular mass (Figure 2F) and an 81% increase in cardiomyocyte cross sectional area 
(Figure 3A and 3B).  Both early and late treatment with EMPA attenuated the increase in left 
ventricular mass (Figure 2F) and diminished cardiomyocyte cross-sectional area compared 
to the vehicle-treated MI group (Figure 3A and B).  Myocardial fibrosis was increased three-
fold in the non-infarcted left ventricle, and this was also was markedly attenuated by 
EMPA treatment (Figure 3B and 3C). The reductions in fibrosis after EMPA treatment were 
accompanied by similar reductions in the expression of the fibrosis markers collagen 1 and 
procollagen (Figure 3E).
Increased myocardial expression of atrial natriuretic peptide (ANP) and an increase in the 
relative expression of foetal (β-MHC) over adult (α-MHC) myocin heavy chain isoform ie. 
β-MHC/α-MHC ratio are generally considered as robust markers for the activation of the 
cardiac fetal gene program.29 Myocardial ANP expression was increased by six-fold in the 
vehicle-treated MI group compared to the sham groups. Both early and late treatment with 
EMPA reduced cardiac ANP expression by 50%. Similarly, the increase in β-MHC/α-MHC ratio 
observed in the MI group was normalized to sham levels after EMPA treatment (Figure 3D).
Effects of empagliflozin on oxidative stress
To investigate the effect of EMPA on myocardial oxidative stress, we determined the 
advanced oxidation protein products (AOPP) level and the expression level of the  superoxide 
generating enzyme NOX2. AOPP was higher in the heart of rats in MI-vehicle group than 
in the sham-vehicle group, and was suppressed by EMPA in both early and late treatment 
(Figure 4A). Similarly, expression of NOX2, was up-regulated in MI-vehicle group, but was 
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Effects of empagliflozin on mitochondrial biogenesis and ATP production
Detailed cardiac and renal analysis of diabetic animal models has revealed tha the SGLT2i 
affect mitochondrial morphology and mitochondrial density.30,31 Mitochondrial content 
and respiratory capacity are also significantly reduced in HF, which is tied to diminished 
expression of the transcription factor PGC-1α.32  To determine whether the favourable effects 
of EMPA on cardiac remodelling were associated with similar recovery of mitochondrial 
biogenesis, mitochondrial content was quantified by normalizing mtDNA to nDNA. We also 
performed a semi-long-run PCR to detect mtDNA damage. As expected,  mtDNA damage 
was also increased after MI (Figure 4B). In addition, mtDNA/nDNA was markedly reduced 
after MI (Figure 4C), accompanied by similar reductions in PGC-1α expression (Figure 4C). 
EMPA normalized PGC-1α expression and partial recovered of mtDNA/nDNA (Figure 4A) 
and mtDNA damage (Figure 4B).  
To verify whether the effects of EMPA on mtDNA damage and the increase in mtDNA/nDNA 
were associated with increased ATP production, we determined the cardiac ATP levels in 
our study. ATP levels were significantly reduced in MI-vehicle group and interestingly, ATP 
levels were significantly restored in MI-EMPA-early group and there was a trend towards 
increased ATP levels in the MI-EMPA-late group (p=0.08) (Figure 4D).
Effects of empagliflozin on myocardial glucose and fatty acid metabolism
HF is accompanied by profound changes in the myocardial utilization of carbon based 
fuels.33 During HF development, cardiac substrate preference first shifts from fatty acids 
to glucose as the primary fuel source, while the later stages of HF are also associated 
with disruption of myocardial glucose uptake and utilization.33 Molecular signatures 
for impaired substrate utilization are, among others, down-regulation of the fatty acid 
transporter carnitine palmitoyltransferase I-α (CPT1-α), downregulation of the glucose 
transporter type 4 (GLUT4) and inhibition of the pyruvate dehydrogenase complex through 
up-regulation of pyruvate dehydrogenase kinase 4 (PDK4).33   Pyruvate dehydrogenase is 
required for carbohydrate  intermediates to enter the Krebs cycle and PDK4 inhibits this 
enzyme complex.33  
As expected, CPT1-α, GLUT4, PGC1-α levels and PDH activity were reduced and PDK4 
expression was increased in cardiac tissue of MI-vehicle group compared to sham-vehicle 
group. Interestingly, EMPA treatment restored the expression of all these markers to sham 
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FIGURE 4. Effect of empagliflozin (EMPA) on oxidative stress, mitochondrial biogenesis and cardiac ATP levels. (A) 
Cardiac advanced oxidation protein products and measurement of mRNA levels to assess oxidative stress. (B) Semi-
long-run polymerase chain reaction was performed using primers specific for mitochondrial DNA fragments in the 
mitochondrial D-loop region to determine mitochondrial DNA damage. (C) Mitochondrial DNA (CYTB)-to-nuclear 
DNA (TRPM-2) ratio and mRNA levels to assess mitochondrial biogenesis. (D) Cardiac ATP levels. EMPA-E, EMPA-
early; EMPA-L, EMPA-late; MI, myocardial infarction; Veh, vehicle. Data are presented as means ± standard errors of 
the mean. *p<0.05 vs. MI-Veh; #p<0.05 vs. Sham-Veh.
Effects of empaglilfozin on ketone metabolism
The disruption of glucose and fatty acid oxidation causes the failing heart to increasingly rely 
on ketone bodies as a fuel source.34,35 EMPA increases circulating ketone levels and indirect 
evidence suggests that EMPA promotes  ketone utilization in patients with diabetes.36 
The beneficial effects of EMPA on cardiac performance could therefore be explained by 
increased myocardial ketone utilization.37,38 
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FIGURE 5. Effect of empagliflozin (EMPA) on glucose metabolism, insulin/glucagon ratio and fatty acid metabolism. 
(A) Measurement of mRNA levels to assess cardiac glucose metabolism. (B) Pyruvate dehydrogenase (PDH) activity. 
(C) Insulin/glucagon ratio. (D) Measurement of mRNA levels to assess fatty acid metabolism. CPT1-𝛼, carnitine 
palmitoyltransferase 1-𝛼; EMPA, empagliflozin; EMPA-E, EMPA-early; EMPA-L, EMPA-late; MI, myocardial infarction; 
Veh, vehicle. Data are presented as means ± standard errors of the mean. *p<0.05 vs. MI-Veh; #p<0.05 vs. Sham-Veh.
Hepatic ketogenesis is induced by reductions in the systemic insulin/glucagon ratio and 
EMPA decreased insulin-to-glucagon ratio (Figure 5C). Consistent with these observations, 
EMPA treatment increased both circulating ketone levels and urinary ketone excretion, in 
sham and MI groups (Figure 6A and 6B). To determine whether the increases in circulating 
ketone levels was also associated with changes in the myocardial capacity to utilize ketone 
bodies we performed a detailed analysis of three critical proteins involved in myocardial 
ketolysis, namely the ketone body transporter monocarboxylate transporter 1 (MCT1), 
ketogenic enzyme β- hydroxy butyrate dehydrogenase (BDH1) and Succinyl-CoA:3-ketoacid 
CoA transferase (SCOT). The expression of the MCT1 and BDH1 gene and the protein 
expression of SCOT were all significantly increased in MI-vehicle group. Furthermore, the 
expression was further increased in both MI-EMPA-early and MI-EMPA-late groups (Figure 
6C and 6D). These findings suggest that ketone bioavailability and cardiac ketone utilization 
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FIGURE 6. Effect of empagliflozin (EMPA) on ketone metabolism. (A) Plasma total ketone body levels. (B) 24 h 
urinary ketone body excretion. (C) Measurement of mRNA levels to assess ketone metabolism. (D) Protein levels 
of succinyl-CoA:3-ketoacid CoA transferase (SCOT). BDH1, ketogenic enzyme 𝛽-hydroxy butyrate dehydrogenase; 
EMPA-E, EMPA-early; EMPA-L, EMPA-late; MCT1, monocarboxylate transporter 1; MI, myocardial infarction; Veh, 
vehicle. Data are presented as means ± standard errors of the mean. *p<0.05 vs. MI-Veh; #p<0.05 vs. Sham-Veh.
DISCUSSION 
In the present study in which we treated non-diabetic rats with LV dysfunction after a large MI 
with the SGLT2i EMPA for 10 weeks, diuresis was markedly increased without affecting kidney 
function, serum glucose and electrolyte levels. EMPA did not influence MI size, but it did 
improve cardiac function and attenuated pathological cardiomyocyte hypertrophy and cardiac 
fibrosis. The beneficial effects of EMPA on cardiac function were associated with favourable 
effects on cardiac metabolism, including reduction of mitochondrial DNA damage and 
oxidative stress, activation of mitochondrial biogenesis, and the restoration of cardiac glucose 
and fatty acid oxidation. Furthermore, EMPA promoted the bioavailability of ketones as well 
as the cardiac capacity of utilize ketone bodies as a fuel source. These findings provide robust 
evidence that EMPA improves cardiac performance in non-diabetic failing hearts, and provides 
further mechanistic insights that provide a rationale for the clinical trials that are underway. 
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SGLT2i have emerged as oral anti-diabetic drugs that reduce cardiovascular events and 
HF hospitalisations in patients with diabetes.11,12,39 Pre-specified secondary analysis of the 
Empagliflozin Cardiovascular  Outcome  Event Trial in Type 2 Diabetes Mellitus Patients 
(EMPA-REG OUTCOME) revealed that EMPA reduced new-onset HF and that the reduction 
in HF hospitalizations was consistent among several subgroups, including patients with 
HF at baseline.11 In the Canagliflozin Cardiovascular Assessment Study (CANVAS), SGLT2i 
canagliflozin also reduced HF hospitalizations compared to placebo and the reductions in 
HF hospitalizations were more pronounced in  patients with a history of HF at baseline.12 
It has to be noted that the history of HF was not robustly adjudicated and that the results 
of these secondary analyses should be considered hypothesis generating. The validity 
of this hypothesis is currently being tested in dedicated cardiovascular outcome trials in 
HF patients with reduced and preserved ejection fraction (NCT03057977, NCT03057951, 
NCT03036124, NCT03619213), which are expected to be completed in 2019-2022. 
Interestingly, these trials have been launched in the absence of robust evidence that SGLT2i 
affect cardiac performance in the absence of diabetes. Indeed, most mechanistic studies 
have been performed in the context of diabetes. Byrne et al.40 reported that EMPA treatment 
prevented the progressive deterioration of cardiac dysfunction in a model of transverse 
aortic constriction surgery in vivo and ex vivo. Another study reported that EMPA reduced 
cardiac hypertrophy and fibrosis in rat model of metabolic syndrome with prediabetes.41 
Moreover, EMPA was also shown to improve diastolic function and ameliorate cardiac 
hypertrophy and fibrosis in female db/db mice.42  Evidence for clinical translation of 
these findings was recently provided by the EMPA-HEART Cardiolink-6 study, which 
demonstrated that 6 months of treatment with EMPA resulted reduced cardiac mass and 
increased LVEF (Verma S., unpublished data) 
In non-diabetic context, a study of Lee et al.43 demonstrated that the SGLT2i dapagliflozin 
and phlorizin attenuated oxidative stress after myocardial infarction in non-diabetic male 
Wistar rats. They also observed that SGLT2i did not reduce the infarct sizes, however it 
did attenuate the cardiac fibrosis.43 Our data extends this observation as we demonstrate a 
reduction in fibrosis and oxidative damage to mitochondrial DNA. In addition, we have now 
added evidence that EMPA also attenuates total myocardial oxidative stress as evidenced by 
reductions in AOPP and NOX2 expression (Figure 4A).
The mechanisms responsible for the beneficial effects of SGLT2i on HF outcomes are a 
matter of intense speculation.15,18 The most obvious beneficial mechanisms could be derived 
from the fact that SGLT2i are potent proximal tubule diuretics. The diuretic effects of EMPA 
were obvious from our study and, in contrast to other diuretics, EMPA did not affect renal 
function and plasma levels of glucose and electrolytes remained normal. These findings are 
consistent with the reno-protective effects observed in patient with diabetes.44,45 Of note, 




is no data to support a prognostic benefit of using diuretics in this population.8 Another 
interesting hypothesis is that the natriuresis induced by EMPA attenuates sodium overload 
in cardiomyocytes through inhibition of the sarcolemmal sodium-hydrogen exchanger. 
Elevated intracellular sodium levels are thought to compromise mitochondrial calcium 
handling and thereby contributes to mitochondrial dysfunction in HF.46 The metabolic 
effects of EMPA observed in our study could thus partially reflect reductions in intracellular 
sodium. Nevertheless, it is hard to comprehend that the profound effects of EMPA on 
cardiac remodelling and cardiac metabolism that we observed are solely explained by their 
diuretic effects, as we did not observe a difference in blood pressure or LV filling pressures 
(Supplementary Table S2).  
Another possible explanation for the beneficial effects of SGLT2i could lie in their effects 
on systemic and cardiac metabolism, which have consistently been observed in models of 
diabetes and heart disease. First, EMPA improves glycaemic control in diabetic patients 
and the caloric loss associated with increased urinary glucose excretion results in weight 
loss.47,48 Weight loss is thought to improve myocardial insulin sensitivity and myocardial 
insulin resistance is common in severe HF, irrespective of the presence of T2DM.33 
Second, several studies have suggested that SGLT2i can restore cardiac mitochondrial 
dysfunction. Indeed, the SGLT2i dapagliflozin restored cardiac PGC1-α in prediabetic 
rats.49 PGC1-α is a critical mediator of mitochondrial biogenesis and the reductions in 
PGC1-α are thought to contribute to mitochondrial dysfunction observed in HF. Mizuno 
et al.30 recently demonstrated that EMPA normalizes the size and number of mitochondria 
in diabetic hearts after a MI. This is consistent with our observation that EMPA restored 
the mtDNA damage, mtDNA/nDNA ratio and restored PGC1-α expression, indicating that 
the effects of SGLT2i on mitochondrial biogenesis can be translated to the non-diabetic 
failing heart. Third, the changes in PDH activity and the expression levels of CPT1, GLUT4 
and PDK4 observed by us and by others,49 suggest that the myocardial capacity to oxidize 
glucose and fatty acids is improved by EMPA. Verma et al.50 recently validated this concept 
by comparing substrate utilisation in a working heart model using hearts from EMPA 
or vehicle-treated diabetic rats. In accordance with our observations, these authors also 
showed that EMPA treatment restored myocardial glucose and fatty acid oxidation to non-
diabetic levels. Fourth, during disease progression diabetic, and failing hearts increasingly 
rely on ketone bodies as a fuels source,37,38,51 and SGLT2i increase circulating ketone levels.36 
The  myocardial capacity to metabolize ketone bodies is increased in HF, reflected by an 
increased expression of ketogenic enzymes such as BDH1.37,38 Ketones are considered to 
be more energy efficient under conditions of metabolic stress as they require less oxygen 
per molecule of ATP generated.37,38  In addition,  ketone oxidation does not inhibit the 
oxidation of other substrates through the Randel cycle,50 and ketones appear to improve 
myocardial blood flow.52 A single dose of EMPA was recently shown to increase myocardial 
ATP, which was strongly correlated with the changes in circulating ketone levels.53 Our 
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findings that EMPA increases the bioavailability and the myocardial utilization of ketone 
bodies which also increases ATP production in non-diabetic rats with LV dysfunction 
after MI are consistent with these observations. Together these data strongly suggest 
that the restoration of cardiac ATP levels by EMPA is at least partially caused by increased 
ketones oxidation. Of note, the result suggests that SGLT2-mediated refuelling of the heart 
contributes to the beneficial effects of EMPA on cardiovascular outcomes. Our study thus 
clearly demonstrates that the salutary effects of EMPA on cardiac metabolism that have 
been described in diabetic models also occur in a non-diabetic context. 
STUDY LIMITATIONS
First, our study provides a detailed insight into the myocardial effects of SGLT2 inhibition 
but was not designed to establish cause and effect of the proposed mechanisms responsible 
for the cardio-metabolic effects. Second, while we describe multiple molecular effect of 
EMPA in the myocardium,  we did not establish the mechanisms underlying these molecular 
changes. More focused mechanistic studies with for instance BDH1 or SCOT knockout mice 
would be required for this purpose.54 Third, we also do not provide direct proof that ketone 
body oxidation is increased in EMPA-treated hearts nor did we quantify the contribution of 
ketone body oxidation to the increase in myocardial ATP levels. This would require detailed 
metabolomics analysis, which is beyond the scope of the current manuscript. In addition, 
the effects of EMPA on ketone body utilization appear to be dependent on the severity of 
cardiac dysfunction as myocardial ketone utilization is not affected in mild HF.50,55 Ketone 
bodies may also have vasodilatory effects on the myocardium, which could explain part of 
the protective effects beyond myocardial ketone utilization.52 Finally, while the post-MI LV 
dysfunction models allows robust and predictable changes in cardiac remodelling and HF 
development, the effects of EMPA may be different in a clinical context. Nevertheless, our 
study provides unique insights into the cardiac effects of EMPA in the non-diabetic failing 
heart and supports the exploration of EMPA as a bona fide HF drug in patients with or 
without diabetes. 
CONCLUSION
Empagliflozin favourably affects cardiac function and remodelling in non-diabetic rats 
with LV dysfunction after MI, associated with substantial improvements in cardiac ATP 
production. Importantly, it did so without renal adverse effects. Our data suggest that 
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The investigation was conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health. The experimental 
protocol was approved by the Animal Ethical Committee of University of Groningen (IvD 
number: 16487-02-001). The study was performed in non-diabetic male Sprague Dawley rats 
weighing 250-280 g (Envigo, The Netherlands). Animals were fed ad libitum and housed 
conventionally in groups of two to four rats with 12:12 h light-dark cycles (N = 8-22/group, 
unless indicated). We followed ARRIVE guidelines when reporting this study.  
Myocardial infarction surgery 
Rats were randomized to HF or sham surgery under isoflurane (2.5%) inhalation anaesthesia. 
After left-sided thoracotomy, HF was induced by permanent ligating of the proximal 
portion of the left coronary artery. Sham operated rats underwent the same procedure but 
without coronary ligation.  
Experimental protocol 
We aimed to study the effect of empagliflozin (EMPA) on both early remodelling after an 
acute MI, as well as the effect of EMPA on the already remodelled heart and chose two 
treatment regimens. In the early treatment group, rats were randomized to EMPA or vehicle 
starting 2 days before surgery and continued until 10 weeks after MI. In the late group, rats 
were stratified according to left ventricular ejection fraction and then randomized to EMPA 
or vehicle starting 2 weeks after MI or sham surgery. After 10 weeks of treatment, rats were 
anesthetized, blood was drawn (either anti-coagulated with EDTA or sodium heparin) and 
the hearts were rapidly excised. Myocardial tissue was sectioned transversally and processed 
for immunohistochemistry or snap-frozen for molecular analysis. Rats with an infarct size 
of  less than 15% were excluded from analysis as these small infarcts are haemodynamically 
fully compensated.
Echocardiography 
Two weeks after surgery and 1 week before termination, the M-mode and 2D 
echocardiography was performed using a Vivid 7 echo machine (GE Healthcare) equipped 
with a 10-MHz phase array linear transducer for serially assessment of cardiac structure 
and function. The measurements included systolic and diastolic LV internal dimensions 
(LVIDs and LVIDD). LV fractional shortening was calculated as FS = (LVIDd – LVIDs) / 
LVIDd x 100 %. LV ejection fraction (LVEF%) was calculated by using the Teichholz method 




Invasive hemodyamic measurements 
Prior to sacrifice, invasive hemodynamics were analysed by aortic and LV catheterization. 
The right carotid artery was isolated, punctured, and a 1.9 F rat pressure‐volume catheter 
(Scisense, London, Ontario, Canada) was inserted into the right carotid artery. The tip of the 
catheter was advanced through the aorta into the LV cavity. Heart rate (HR), left ventricular 
end-systolic (LVESP) and end-diastolic (LVEDP) pressures, and maximal rates of increase 
and decrease in developed LV pessures (dP/dtmax and dP/dtmin) were determined. The 
data were acquired using a PowerLab data acquisition system (ADInstruments, Colorado 
Springs, CO) and analyzed with a LabChart 8 software.
Infarct size, cardiomyocyte size and interstitial fibrosis measurement 
Rats were euthanized under isoflurane anaesthesia. Heart were rapidly excised and 
weighed. The mid-papillary slice of the LV was fixed in 4% formaldehyde and paraffin-
embedded. Infarct size was calculated as percentage of the scar length to the total LV 
circumference on Masson trichrome-stained section. Furthermore, Masson trichrome 
staining was also used to evaluate the extent of interstitial fibrosis. Hamamatsu microscope 
was used to capture the whole tissue section and Aperio ImageScope software was used to 
quantify fibrosis in the left ventricular free wall remote from the infarction. Finally, sections 
were stained with FITC Labelled wheat germ agglutinin (WGA) to determine cardiomyocyte 
size. Cell size from transversally cut cardiomyocytes in the left ventricular free wall remote 
from the infarcted area was measured using image analysis (Zeiss KS400, Germany) and 
quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The 
investigators analysing the data were blinded to the treatment allocation.
Metabolic cage 
Two weeks before termination, rats were placed in metabolic cages to monitor 24-hour 
water and food intake and 24-hour urine collection. The metabolic cages consist of an upper 
chamber with a grid floor where the rat is housed; and a lower chamber with specialized 
funnel that separates fecal pellets and urine. After 24-hour housed in the metabolic cage, 
under isoflurane anesthesia, blood samples were drawn from tail vein and plasma was 
collected. Plasma and urine were stored at -80 ˚C for later analysis.
Blood measurements 
Blood samples were obtained via tail vein at regular intervals under isoflurane anaesthesia 
to monitor blood glucose and haematocrit levels.  At sacrifice, 8 ml of blood was drawn from 
the abdominal aorta and urine was obtained from the bladder. Plasma creatinine and glucose 
were determined enzymatically on the Roche/Hitachi Cobas system (Roche Germany). Plasma 
sodium and potassium were measured by ion-selective electrode methods on the Roche/Hitachi 
Cobas system (Roche Germany). Plasma total ketone body concentrations were quantified via a 
cyclic enzymatic method using Autokit Total Ketone Body (Wako Chemicals, Germany). 




Urine creatinine and glucose were determined enzymatically on the Roche/Hitachi cobas 
system (Roche Germany). Urine sodium and potassium were measured by ion-selective 
electrode methods on the Roche/Hitachi Cobas system (Roche, Germany). Urine total 
ketone body concentrations was quantified via a cyclic enzymatic method using Autokit 
Total Ketone Body (Wako Chemicals, Germany). Total urinary protein was measured by 
turbidimetric method on the Roche/Hitachi Cobas system (Roche Germany). Creatinine 
clearance, as an estimation for glomerular filtration rate, was calculated from urinary and 
plasma creatinine levels. Creatinine clearance = (urine creatinine x urine flow) / (plasma 
creatinine x body weight) and presented as mL/min/kg body weight. 
Quantitative real-time polymerase chain reaction
RNA was extracted from the non-infarcted left ventricular free wall remote from the 
infarction using TRIzol reagent (Invitrogen Corp., Carlsbad, CA, USA) and the NanoDrop 
device was used to measure RNA concentration. Random primer mix was used to prepare 
first-stranded DNA and thereafter used as a template for quantitative real-time reverse-
transcriptase-PCR (qRT-PCR) (25 ng/reaction). mRNA levels obtained by a qRT-PCR using 
C1000 Thermal Cycler CFX384 Real-Time PCR Detection System (Bio-Rad Laboratories, 
Veenendaal, The Netherlands). 36B4 reference gene were used to correct all measured 
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FIGURE S1. (A) Daily food intake. (B) Daily water intake. (C) Body weight at termination. Veh, Vehicle; EMPA, 























































































FIGURE S2. (A) % Hematocrit levels. (B) Plasma glucose levels. (C) Plasma sodium levels. (D) Plasma potassium 
levels. Veh, Vehicle; EMPA, empagliflozin; EMPA-E, EMPA early; EMPA-L, EMPA late. Data are presented as means ± 
SEM. *p< 0 05 vs. MI-Veh; #p< 0.05 vs. Sham-Veh.




TABLE S1. List of primers used in this study.
















Mt D-loop short TCGGATGCCTTCCTCAACATAG TGCTGACCTTCATGCCTTGAC
Mt D-loop long CTACCATCCTCCGTGAAATC ACCAACCCTGAGAGGTATAG
TABLE S2. Hemodynamics parameters for sham-operated and post-MI rats.
Parameters Sham-Veh Sham-EMPA MI-Veh MI-EMPA-E MI -EMPA-L
SBP (mmHg) 114 ± 4 116 ± 4 118 ± 4 106 ± 4 113 ± 4
DBP (mmHg) 81 ± 4 82 ± 4 85 ± 3 75 ± 4 80 ± 4
LVESP (mmHg) 88 ± 9 106 ± 5 110 ± 4 93 ± 7 107 ± 4
LVEDP (mmHg) 13 ± 4 13 ± 1 14 ± 2 16 ± 1 15 ± 1
corrected dP/dt max 59 ± 2 53 ± 1 53 ± 2 50 ± 1 47 ± 2
corrected dP/dt min -64 ± 1 -55 ± 1 -52 ± 2 -47 ± 2 -45 ± 3
Data are presented as means ± SEM. *p< 0.05 vs. MI-Veh; #p< 0.05 vs. Sham-Veh.
SBP, systolic blood pressure; DBP, diastolic blood pressure; LVESP, left ventricular end-sytolic pressure; LVEDP, 
left ventricular end-diastolic pressure, dP/dtmax and dP/dtmin, the maximal rate of increase and decrease of left 




TABLE S3. Echocardiographic parameters for sham-operated and post-MI rats.
Parameters Sham-Veh Sham-EMPA MI-Veh MI-EMPA-E MI-EMPA-L
IVSd 1.91 ± 0.17 1.86 ± 0.07 1.67 ± 0.10 1.60 ± 0.11 1.81 ± 0.11
LVIDd 7.89 ± 0.27 8.03 ± 0.15 9.47 ± 0.22# 9.36 ± 0.24 9.10 ± 0.43
LVPWd 2.02 ± 0.15 2.32 ± 0.19 2.21 ± 0.14 2.06 ± 0.15 1.94 ± 0.09
IVSs 3.42 ± 0.20 3.45 ± 0.15 2.35 ± 0.17# 2.97 ± 0.36 2.89 ± 0.87
LVIDs 4.47 ± 0.15 4.30 ± 0.17 7.17 ± 0.27# 6.35 ± 0.34 6.29 ± 0.54
LVPWs 3.28 ± 0.17 3.24 ± 0.14 2.84 ± 0.14 2.95 ± 0.13 2.74 ± 0.16
FS (%) 43.9 ± 3.2 46.1 ± 2 23.1 ± 1.2# 32.6 ± 2.3* 31.7 ± 3.5*
EF (%) 73 ± 3 75 ± 2 43 ± 2# 54 ± 3* 52 ± 4*
Data are presented as means ± SEM. *p<0.05 vs. MI-Veh; #p<0.05 vs. Sham-Veh.
IVS, interventricular in diastole (d) and systole (s), respectively; LVID, left ventricular internal dimensions in both 
diastole (d) and systole (s); LVPW, the thickness of left ventricle posterior wall in diastole (d) and systole (s); FS, 
fractional shortening; EF, left ventricular ejection fraction.
